Browsing by Subject "Prognostic"

Now showing 1 - 3 of 3
  • Thumbnail Image
    Publication
    Restricted
    Left-sided infective endocarditis in patients with liver cirrhosis
    (Elsevier, 2015-09-25) Ruiz-Morales, J.; Ivanova-Georgieva, R.; Fernández-Hidalgo, N.; García-Cabrera, E.; Miró, Jose M.; Muñoz, P.; Almirante, B.; Plata-Ciézar, A.; González-Ramallo, V.; Gálvez-Acebal, J.; Fariñas, M.C.; Bravo-Ferrer, J.M.; Goenaga-Sánchez, M.A.; Hidalgo-Tenorio, C.; Goikoetxea-Agirre, J.; Alarcón-González, A. de; García-Vázquez, Elisa; Endocarditis Group-Grupo de Apoyo al Manejo de la Endocarditis en España (GAMES); Spanish Network for Research in Infectious Diseases (REIPI); Medicina
    Objective: To evaluate the course of left-sided infective endocarditis (LsIE) in patients with liver cirrhosis (LC) analyzing its influence on mortality and the impact of surgery. Methods: Prospective cohort study, conducted from 1984 to 2013 in 26 Spanish hospitals. Results: A total of 3.136 patients with LsIE were enrolled and 308 had LC: 151 ChildePugh A,103 B, 34 C and 20 were excluded because of unknown stage. Mortality was significantly higher in the patients with LsIE and LC (42.5% vs. 28.4%; p < 0.01) and this condition was in general an independent worse factor for outcome (HR 1.51, 95% CI: 1.23e1.85; p < 0.001). However, patients in stage A had similar mortality to patients without cirrhosis (31.8% vs. 28.4% p Z NS) and in this stage heart surgery had a protective effect (28% in operated patients vs. 60% in non-operated when it was indicated). Mortality was significantly higher in stages B (52.4%) and C (52.9%) and the prognosis was better for patients in stage B who underwent surgery immediately (mortality 50%) compared to those where surgery was delayed (58%) or not performed (74%). Only one patient in stage C underwent surgery. Conclusions: Patients with liver cirrhosis and infective endocarditis have a poorer prognosis only in stages B and C. Early surgery must be performed in stages A and although in selected patients in stage B when indicated
  • Thumbnail Image
    Publication
    Open Access
    Prognostic index expression of cyclin-D1, cerbB-2 and VEGF metastases vs corresponding primary cancers and metastatic vs non-metastatic adenocarcinomas
    (Murcia : F. Hernández, 2008) Roger Parra, Edwin; Young Park, Ji; Midori Saito, Dalva; Yae Takagaki, Teresa; Ribeiro Rodrigues, Olavo; Capelozzi, Vera Luiza
    The prognostic relevance of different molecular markers in lung cancer is a crucial issue still worth investigating, and the specimens collected and analyzed represent a valuable source of material. Cyclin- D1, c-erbB-2 and vascular endothelial growth factor (VEGF) have shown to be promising as prognosticators in human cancer. In this study, we sought to examine the importance of Cyclin-D1, c-erbB-2 and VEGF, and to study the quantitative relationship among these factors and disease progression in metastases vs corresponding primary cancer, and metastatic vs non metastatic cancers. Material and Methods: We used immunohistochemistry and morphometric analysis to evaluate the amount of tumour staining for Cyclin-D1, cerbB- 2 and VEGF in 52 patients with surgically excised ademocarcinoma of the lung, and the outcome for our study was survival time until death from hematogenic metastases. Results: Metastasis presented lower c-erbB-2 expression than corresponding primary cancers (p=0.02). Cyclin-D1 and VEGF expression were also lower in metastases than in corresponding primary cancers, but this difference did not achieve statistical significance. Non-metastatic cancers also presented significantly lower Cyclin-D1 and c-erbB-2 expression than metastatic cancers (p<0.01 and p<0.01, respectively). Equally significant was the difference between higher cerbB- 2 expression by metastatic cancers compared to non-metastatic cancers (p=0.02). Considering survival in Kaplan-Maier analysis, Cyclin-D1 (p=0.04), c-erbB-2 (p=0.04) and VEGF (p<0.01) were important predictors of survival in metastatic cancers.
  • Thumbnail Image
    Publication
    Open Access
    TRIM11 expression in non-small cell lung cancer is associated with poor prognosis
    (Universidad de Murcia, Departamento de Biologia Celular e Histiologia, 2024) Kuempers, Christiane; Jagomast, Tobias; Paulsen, Finn Ole; Heidel, Carsten; Bohnet, Sabine; Schierholz, Stefanie; Reischl, Markus; Dreyer, Eva; Olchers, Till; Reck, Martin; Kirfel, Jutta; Perner, Sven
    Background. Despite promising results of targeted therapy approaches, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related death. Tripartite motif containing 11 (TRIM11) is part of the TRIM family of proteins, playing crucial roles in tumor progression. TRIM11 serves as an oncogene in various cancer types and has been reported to be associated with a poor prognosis. In this study, we aimed to investigate the protein expression of TRIM11 in a large NSCLC cohort and to correlate its expression with comprehensive clinico-pathological data. Methods. Immunohistochemical staining of TRIM11 was performed on a European cohort of NSCLC patients (n=275) including 224 adenocarcinomas and 51 squamous cell carcinomas. Protein expression was categorized according to staining intensity as absent, low, moderate and high. To dichotomize samples, absent and low expression was defined as weak and moderate and high expression was defined as high. Results were correlated with clinico-pathological data. Results. TRIM11 was significantly more highly expressed in NSCLC than in normal lung tissue and significantly more highly expressed in squamous cell carcinomas than in adenocarcinomas. We found a significantly worse 5-year overall survival for patients who highly expressed TRIM11 in NSCLC. Conclusions. High TRIM11 expression is linked with a poor prognosis and might serve as a promising novel prognostic biomarker for NSCLC. Its assessment could be implemented in future routine diagnostic workup.